Providers understand the threat of depression

Overwhelming Prevalence

~50 million people with depression in US

~350M worldwide

Personal and Social Impact

~48K suicides/year
Reduced quality of personal & family life
Reduced work productivity

Clinical Challenges

1/2 of patients do not respond adequately to first Rx; assessment takes weeks

~60% of patients who do not benefit from first Rx do not try another

Diagnostic Accuracy

Lack of support for PCPs who diagnose and determine treatment for >65% of cases, as well as providing follow-up care

MoodMark® has the potential to support rapid, objective diagnosis and treatment using a simple blood draw

Confirm depression diagnosis and severity

Differentiate from other conditions & identify co-morbid conditions

Identify appropriate medication in treatment resistant patients

Objectively supplement current questionnaire diagnosis of depression without patient bias

Evaluate medication effectiveness potential within days of therapy initiation, not weeks

Monitor patient response

Speed:
One-week diagnostic and prescription effectiveness test turnarounds

Certainty:
Biological determination vs. subjective surveys and patient estimations

Cost:
A single blood test vs. multiple provider visits

Detection:
Test patients as part of routine blood draws to address widely undiagnosed condition